赵晓宇，博士
上海市浦江人才
复旦大学感染与健康研究院青年研究员
上海感染与免疫科技创新中心PI
【研究方向】
病毒致病机制与抗病毒策略研究
【个人简介】
赵晓宇博士于2021年获得香港大学博士学位，随后加入复旦大学开展博士后研究，2024年起任复旦大学感染与健康研究院青年研究员、上海感染与免疫科技创新中心PI。主要从事新发突发病毒的致病机制解析、免疫应答研究及抗病毒策略开发。累计发表SCI论文50余篇，其中以第一作者或通讯作者（含共同）在Cell Host & Microbe、Cell Discovery、Nature Communications、Journal of Virology、MedComm、Nature Reviews Immunology等国际权威期刊发表论文20 篇。
【科研项目与荣誉】
主持国家自然科学基金青年项目和上海市白玉兰人才计划浦江项目，并作为骨干成员参与国家重点研发计划和上海高水平地方高校创新团队等重大科研项目。入选2021年复旦大学“超级博士后”计划、2022年博士后国际交流计划引进项目、2023年上海市浦江人才计划等人才激励计划，并荣获2022年度“谈家桢博士后学者奖”一等奖等荣誉。
【学术任职】
担任上海市药学会生化与生物技术药物专业委员会青年委员，期刊Military Medical Research青年编委，以及Virology Journal和Frontiers in Virology期刊的Associate Editor、Frontiers in Immunology期刊的Guest Editor以及Scientific Reports期刊的编委会成员。
【发表论文】
2025
1. Qiao R, Liu Y, Mao Q, Li J, Lu Y, Shi J, Li C, Yu J, Gong J, Wang X, Shao Y, Sun L, Zhang W, Yu H, Chu H#, Wang P#, Zhao X#. Novel trispecific neutralizing antibodies with enhanced potency and breadth against pan-sarbecoviruses. MedComm, 2025.
2. Zhao X# (co-corresponding author), Yang L, Mi Y, Lu Y, Sun B, Zhang Y, Yang Y, Sun Y, Zhang L, Lin L, Wu J#, Zhang W#. Current Landscape with an Analytical Outlook: Chikungunya Virus Vaccine Development. The Innovation Medicine, 2025.
3. Shi J*, Zhao X*# (co-corresponding author), Jin X*, Li J*, Liu Y*, Liu H*, Hu YF*, Chen Z, Xiao Y, Wang L, Wang Y, He Y, Chai Y, Hu B, Shuai H, Wang Y, Li X, Jiang S, Zhang Y, Zhang X, Chan WM, Chen LL, Cai JP, Sui B, Zhang H, Yang D, Zhu L, Yuan S, Zhou J, Huang JD, Yuen KY, To KKW, Chan JFW, Zhang BZ, Wang Q, He M#, Sun L#, Wang P#, Chu H#. Intrinsic pathogenicity, virological features, and immune evasion of SARS-CoV-2 Omicron KP.2, KP.3, and KP.3.1.1. Nature Communications, 2025.
4. Xie M*, Qiu Y*, Zhao X* (co-first author), Shi J*, Liu Y*, Zhang Q*, He J*, Li J*, Liu L, Sun S, Zhu Y, Mao Q, Long Y, Oliveira TY, Wang Z, Zhou Y, Yan Y, Xia A, Zai W, Mayer CT, Xie Y, Jiang S, Lu L, Xia R#, Wu F#, Sun L#, Wang P#, Chu H#, Wang Q#. Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution. Nature Communications, 2025.
5. Qiao R, Li J, Gong J, Shao Y, Yu J, Chen Y, Lu Y, Yang L, Lin L, Hu Z, Wang P#, Zhao X#, Zhang W. Evolving SARS-CoV-2 vaccines: from current solutions to broad-spectrum protection. Vaccines, 2025.
6. Zhao X, Chu H. Decoding broadly neutralizing antibodies: a milestone in SFTSV therapy. EBioMedicine, 2025.
2024
1. Zhao X# (co-corresponding author), Qiao R, Hao M, Xu L, Wang D, Lu Y, Li J, Wu J, Li Y, Cheng T, Zhang W, Zhao J#, Wang P#. Vascular endothelial growth factor receptor 2 as a potential host target for the inhibition of enterovirus replication. Journal of Virology, 2024.
2. Zhao X* (co-first author), Qiu T*, Huang X*, Mao Q*, Wang Y*, Qiao R*, Mao T, Wang Y, Li J, Luo C, Yoon C, Wang X, Li C, Cui Y, Zhao C, Li M, Chen Y, Cai G, Geng W, Hu Z, Cao J, Zhang W, Cao Z#, Chu H#, Sun L#, Wang P#. Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination. Cell Discovery, 2024.
3. Liu Y*, Zhao X* (co-first author), Shi J*, Wang Y*, Liu H*, Hu YF*, Hu B, Shuai H, Yuen TTT, Chai Y, Liu F, Gong H, Li J, Wang X, Jiang S, Zhang X, Li X, Wang L, Hartnoll M, Zhu T, Hou Y, Huang X, Yoon C, Wang Y, He Y, Zhou M, Du L, Zhang X, Chan W, Chen L, Cai J, Yuan S, Zhou J, Huang JD, Yuen KY, To KKW, Chan JFW#, Zhang BZ#, Sun L#, Wang P#, Chu H#. Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3. Nature Communications, 2024.
2023
1. Qiao R, Tang W, Li J, Li C, Zhao C, Wang X, Li M, Cui Y, Chen Y, Cai G, Wu Q, Zhao X# (co-corresponding author), Wang P#. Structure-based virtual screening of ROCK1 inhibitors for the discovery of Enterovirus-A71 antivirals. Virology, 2023.
2. Chen Y*, Zhao X* (co-first author), Zhou H*, Zhu H, Jiang S#, Wang P#. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nature Reviews Immunology, 2023.
2022
1. Zhao X, Li C, Chiu MC, Qiao R, Jiang S, Wang P#, Zhou J#. Rock1 is a novel host dependency factor of human enterovirus A71: Implication as a drug target. Journal of Medical Virology, 2022.
2. Wang X*, Zhao X* (co-first author), Cui Y*, Qiao R*, Li M*, Chen Y, Yang L, Jiang S, Wang P#. Neutralization of distinct Omicron sublineages by longitudinal vaccination sera. Journal of Medical Virology, 2022.
3. Wang X*, Zhao X* (co-first author), Song J*, Wu J*, Zhu Y*, Li M, Cui Y, Chen Y, Yang L, Liu J, Zhu H, Jiang S, Wang P#. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerging Microbes & Infections, 2022.
4. Wang X, Ai J, Li X*, Zhao X* (co-first author), Wu J*, Zhang H*, He X*, Zhao C, Qiao R, Li M, Cui Y, Hu Z, Xu C, Zhang W, Wang P#. Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera. Cell Discovery, 2022.
5. Ai J*, Wang X*, He X*, Zhao X* (co-first author), Zhang Y*, Jiang Y*, Li M, Cui Y, Chen Y, Qiao R, Li L, Yang L, Li Y, Hu Z, Zhang W#, Wang P#. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host & Microbe, 2022.
2021
1. Zhao X, Li C, Liu X, Chiu MC, Wang D, Wei Y, Chu H, Cai JP, Chan IHY, Wong KKY, Chan JFW, To KKW, Yuen KY#, Zhou J#. Human intestinal organoids recapitulate enteric infections of enterovirus and coronavirus. Stem Cell Reports, 2021.
2. Tsang JO*, Zhou J*, Zhao X* (co-first author), Li C, Zou Z, Yin F, Yuan S, Yeung ML, Chu H, Chan JFW#. Development of three-dimensional human intestinal organoids as a physiologically relevant model for characterizing viral replication kinetics and antiviral susceptibility of enteroviruses. Biomedicines, 2021.
2020
1. Zhao X, Chu H, Wong BHY, Chiu MC, Wang D, Li C, Liu X, Yang D, Poon VKM, Cai J, Chan JFW, To KKW, Zhou J#, Yuen KY#. Activation of C-type lectin receptor and RIG-I-like receptors contributes to proinflammatory response in MERS-CoV–infected macrophages. Journal of Infectious Diseases, 2020.
